Tri Locum Partners LP Blueprint Medicines Corp Transaction History
Tri Locum Partners LP
- $387 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$614 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$604 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$543 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$299 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$227 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.52B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...